Literature DB >> 17206399

High bone mineral density in pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K.

A F Schilling1, C Mülhausen, W Lehmann, R Santer, T Schinke, J M Rueger, M Amling.   

Abstract

INTRODUCTION: Pycnodysostosis is typically associated with short stature, multiple fractures without adequate trauma and high bone density on x-ray. The increased bone density is due to a genetic defect of cathepsin K, leading to dysfunctional osteoclastic bone resorption and bone remodeling. We wanted to know how this defect influences the trabecular and cortical volumetric bone mineral density of long bones as measured quantitatively by pQCT.
METHODS: Three siblings of a consanguineous family were admitted to our hospital because of multiple fractures. Pycnodysostosis was diagnosed based on the clinical presentation with the characteristic dense appearance of their bones on x-ray. The distal and proximal radius of the patients and of control subjects was scanned using a Stratec XCT-2000 pQCT scanner and data were processed using the software provided by the manufacturer. Genomic DNA was extracted from blood samples of all three patients and their parents. The coding exons of the cathepsin K gene (CTSK) were amplified and sequenced.
RESULTS: The patients displayed the typical features of pycnodysostosis: Short stature, delay of closure of the fontanelles, hypoplasia of the maxilla, spondylolysis of the lumbar spine, stubby hands and feet and a history of multiple fractures. Volumetric bone density was much higher in pycnodysostotic bone than in the control bones 686 +/- 28 mg/cm(3) in patients vs. 290 +/- 6 mg/cm(3) in controls; p = 0.001), especially in the trabecular compartment (733 +/- 26 mg/cm(3) in patients vs. 195 +/- 8 mg/cm(3) in controls; p < 0.001), but also in the cortical bone (1108 +/- 22 in patients vs. 1020 +/- 17 in controls; p < 0.01). In contrast to this finding, the patients displayed an elevation of alkaline phosphatase in the serum and free deoxypyridinoline-crosslinks (DPD) in the urine, suggesting osteomalacia. Sequencing of the cathepsin K gene revealed homozygosity for a novel missense mutation in all three patients predicting the amino acid exchange from arginine to tryptophan at position 46 (R46W).
CONCLUSION: We present here for the first time quantitative data on the mineral density of bones of pycnodysostotic patients with a novel mutation in the propeptide of cathepsin K. The elevated bone mineral density in the cortex and the changes in the serum markers suggest an effect of cathepsin K not only on bone volume, but also on bone mineralization. This might in part explain the increased susceptibility to fractures of patients with pycnodysostosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17206399     DOI: 10.1007/s00198-006-0311-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  48 in total

1.  A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis.

Authors:  M R Johnson; M H Polymeropoulos; H L Vos; R I Ortiz de Luna; C A Francomano
Journal:  Genome Res       Date:  1996-11       Impact factor: 9.043

2.  [Pyknodysostosis].

Authors:  P MAROTEAUX; M LAMY
Journal:  Presse Med       Date:  1962-04-25       Impact factor: 1.228

3.  Structure and chromosomal assignment of the human cathepsin K gene.

Authors:  B D Gelb; G P Shi; M Heller; S Weremowicz; C Morton; R J Desnick; H A Chapman
Journal:  Genomics       Date:  1997-04-15       Impact factor: 5.736

4.  Bone densities and bone size at the distal radius in healthy children and adolescents: a study using peripheral quantitative computed tomography.

Authors:  C M Neu; F Manz; F Rauch; A Merkel; E Schoenau
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

5.  Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.

Authors:  B D Gelb; G P Shi; H A Chapman; R J Desnick
Journal:  Science       Date:  1996-08-30       Impact factor: 47.728

6.  A case of pycnodysostosis with growth hormone deficiency.

Authors:  S Darcan; M Akisü; B Taneli; G Kendir
Journal:  Clin Genet       Date:  1996-11       Impact factor: 4.438

7.  Defective growth hormone secretion in children with pycnodysostosis and improved linear growth after growth hormone treatment.

Authors:  A T Soliman; A Rajab; I AlSalmi; A Darwish; M Asfour
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

8.  Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

Authors:  G B Stroup; M W Lark; D F Veber; A Bhattacharyya; S Blake; L C Dare; K F Erhard; S J Hoffman; I E James; R W Marquis; Y Ru; J A Vasko-Moser; B R Smith; T Tomaszek; M Gowen
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

9.  Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption.

Authors:  T Inui; O Ishibashi; T Inaoka; Y Origane; M Kumegawa; T Kokubo; T Yamamura
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

10.  The collagenolytic activity of cathepsin K is unique among mammalian proteinases.

Authors:  P Garnero; O Borel; I Byrjalsen; M Ferreras; F H Drake; M S McQueney; N T Foged; P D Delmas; J M Delaissé
Journal:  J Biol Chem       Date:  1998-11-27       Impact factor: 5.157

View more
  19 in total

1.  Accordion Maneuver with Modified Ilizarov Frame for treatment of recalcitrant nonunion of shaft of femur in a patient with Pycnodysostosis.

Authors:  Ranjit Kumar Baruah; Russel Haque
Journal:  J Clin Orthop Trauma       Date:  2016-09-28

Review 2.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

3.  Novel Compound Heterozygous Mutations in the Cathepsin K Gene in Japanese Female Siblings with Pyknodysostosis.

Authors:  M Matsushita; H Kitoh; H Kaneko; K Mishima; Y Itoh; T Hattori; N Ishiguro
Journal:  Mol Syndromol       Date:  2012-03-06

4.  Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.

Authors:  Le T Duong
Journal:  Bonekey Rep       Date:  2012-05-02

5.  Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.

Authors:  Cristiano A F Zerbini; Michael R McClung
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

Review 6.  Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.

Authors:  Matthew T Drake; Bart L Clarke; Merry Jo Oursler; Sundeep Khosla
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

7.  Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

Authors:  S Aubrey Stoch; Stefan Zajic; Julie A Stone; Deborah L Miller; Lucas van Bortel; Kenneth C Lasseter; Barnali Pramanik; Caroline Cilissen; Qi Liu; Lida Liu; Boyd B Scott; Deborah Panebianco; Yu Ding; Keith Gottesdiener; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 8.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

9.  Pedicle stress fracture: an unusual complication of pycnodysostosis.

Authors:  Paul Ornetti; Clement Prati; Cecile Fery-Blanco; Gerald Streit; Eric Toussirot; Daniel Wendling
Journal:  Clin Rheumatol       Date:  2007-09-22       Impact factor: 2.980

10.  A mutation in CTSK gene in an autosomal recessive pycnodysostosis family of Pakistani origin.

Authors:  Muhammad Naeem; Sabeen Sheikh; Wasim Ahmad
Journal:  BMC Med Genet       Date:  2009-08-12       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.